Insights on the Global Depression Treatment Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027
The global depression treatment Market is anticipated to grow at a CAGR of 4.1% during the forecast period (2020-2027). The increasing number of FDA approvals for antidepressants along with the expansion in pipeline products by key market players are certain factors driving the growth of the depression treatment industry.
To Request a Sample of our Report on Global Depression
Treatment Market: https://www.omrglobal.com/request-sample/depression-treatment-market
·
In February 2021, Zydus Cadila has received US FDA
approval for Nortriptyline Hydrochloride Capsules USP. The capsules come up in
the strength of 10 mg, 25 mg, 50 mg, and 75 mg. Nortriptyline Hydrochloride
Capsules USP is majorly used for the treatment of depression.
·
Moreover, in July 2020, VistaGen Therapeutics, a US-based
biopharmaceutical company had received US FDA approval for PH94B under Phase 3
development to treat acute anxiety and mental illness in adult patients with a
social anxiety disorder (SAD). PH94B is an investigational rapid-onset
neurosteroid nasal spray majorly used for the treatment of social anxiety
disorder.
·
Furthermore, in March 2019, Johnson & Johnson’s
ketamine-derived nasal spray Spravato for treatment-resistant depression has
been approved by the FDA. The Spravato CIII Nasal Spray is used for the
treatment of depressive disorder in adults with a high risk of major depressive
disorder (MDD). Thus, these approvals by the FDA for antidepressant drugs
produced by major key players, the depression treatment market is expected to
witness significant growth during the forecast period.
Market Coverage
·
The market number available for – 2021-2027
·
Base year- 2020
·
Forecast period- 2021-2027
Segment Covered-
·
By Drug Type
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
·
Competitive Landscape- Eli Lilly and Company, Pfizer, Inc., Johnson
& Johnson, Merck & Co., Inc., H. Lundbeck A/S, F. Hoffmann-La Roche
Ltd, and Others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Depression Treatment Market is Available at: https://www.omrglobal.com/industry-reports/depression-treatment-market
Global Depression Treatment Market Report Segment
By Drug Type
·
Selective Serotonin Reuptake Inhibitors
·
Tricyclic Antidepressants
·
Serotonin-Norepinephrine Reuptake Inhibitors
·
Monoamine Oxidase Inhibitors
·
Others
Global Depression Treatment Market Report Segment by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Company Profiles
·
Alkermes Plc
·
Allergen Plc
·
AstraZeneca plc
·
Bausch Health Companies, Inc.
·
Eli Lilly and Co.
·
F. Hoffmann-La Roche AG
·
Garmin Ltd.
·
GlaxoSmithKline plc
·
H. Lundbeck A/S
·
Johnson & Johnson Services, Inc.
·
Lief Therapeutics
·
Lupin Ltd.
·
MagVenture, Inc.
·
Mylan N.V.
·
Novartis AG
·
Otsuka Pharmaceutical Co., Ltd.
·
Pfizer, Inc.
·
Sanofi SA
·
Takeda Pharmaceutical Co. Ltd.
·
Teva Pharmaceutical Industries Ltd.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment